Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC Cyclacel regains compliance with Nasdaq listing rule after filing Form-10Q for the quarter ended September 30, 2023

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...